Solara Active Pharma Sciences Ltd Q4FY21 consolidated PAT at Rs. 56.65 crore

Solara Active Pharma Sciences Ltd has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.453.99 crores during the period ended March 31, 2021 as compared to Rs.434.98 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.56.65 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.65.80 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.15.24 for the period ended March 31, 2021 as compared to Rs.17.29 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 453.99 crs	₹ 434.98 crs	4.37%
Net Profit	₹ 56.65 crs	₹ 65.80 crs	-13.91%
EPS	₹ 15.24	₹ 17.29	-11.86%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.453.99 crores during the period ended March 31, 2021 as compared to Rs.308.90 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.56.65 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.17.82 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.15.24 for the period ended March 31, 2021 as compared to Rs.6.21 for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 453.99 crs	₹ 308.90 crs	46.97%
Net Profit	₹ 56.65 crs	₹ 17.82 crs	217.9%
EPS	₹ 15.24	₹ 6.21	145.41%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.1645.65 crores during the 12 months period ended March 31, 2021 as compared to Rs.1349.27 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.221.40 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.114.61 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.64.52 for the 12 months period ended March 31, 2021 as compared to Rs.42.82 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 1645.65 crs	₹ 1349.27 crs	21.97%
Net Profit	₹ 221.40 crs	₹ 114.61 crs	93.18%
EPS	₹ 64.52	₹42.82	50.68%

Commenting on the performance, Bharath Sesha, the MD & CEO of the Company, remarked "Solara's excellent execution and strong customer partnerships have powered us to a record annual performance. We have delivered exceptional YoY growth on all key financial metrics. The drive and passion of our employees have anchored Solara as a partner of choice with our customers.

We continue to grow our business in both regulated and other markets leading to a balanced market footprint. I am very proud to share that our cost improvement programs continue to deliver superior results. I am confident that the Solara efficiency machine will maintain this momentum in the future.

Our strategy execution has gained traction with the announced merger of Solara and Aurore. It is EPS accretive immediately for Solara shareholders. We are very excited about the synergies this combination will generate. The merger adds momentum to our CRAM s growth, bolsters our presence in focus markets, enhances our product portfolio and boosts R&D velocity.

While we retain a strong position on base products, we will scale up high margin new products and our CRAM s business, leading to continued growth momentum for Solara."

Shares of Solara Active Pharma Sciences Ltd was last trading in BSE at Rs.1610.8 as compared to the previous close of Rs. 1538.9. The total number of shares traded during the day was 32884 in over 3549 trades.

The stock hit an intraday high of Rs. 1646.5 and intraday low of 1512.1. The net turnover during the day was Rs. 52689971.

Source : Equity Bulls

Keywords